Subgroups | Revefenacin 175 μg (n = 395) | Placebo (n = 417) |
---|---|---|
ITT | ||
Evaluable n | 288 | 276 |
Odds ratio (95% CI) | 1.53 (1.10, 2.13), p = 0.0116 | |
FEV130%–< 50% pred | ||
Evaluable n | 96 | 78 |
Odds ratio (95% CI) | 1.99 (1.04, 3.81), p = 0.0368 | |
FEV1 < 30% pred | ||
Evaluable n | 16 | 7 |
Odds ratio (95% CI) | 2 × 1010 (3.05 × 107,126 × 109), p < 0.001 | |
2011 GOLD category D | ||
Evaluable n | 103 | 81 |
Odds ratio (95% CI) | 2.52 (1.34, 4.76), p = 0.0042 | |
ICS use | ||
Evaluable n | 134 | 105 |
Odds ratio (95% CI) | 1.23 (0.74, 2.03), p = 0.4291 | |
LABA or ICS/LABA use | ||
Evaluable n | 118 | 85 |
Odds ratio (95% CI) | 1.34 (0.77, 2.35), p = 0.2995 | |
> 65 years | ||
Evaluable n | 133 | 119 |
Odds ratio (95% CI) | 1.11 (0.67, 1.84), p = 0.6897 | |
> 75 years | ||
Evaluable n | 28 | 25 |
Odds ratio (95% CI) | 0.58 (0.19, 1.81), p = 0.3506 | |
Reversible to ipratropium and albuterol | ||
Evaluable n | 66 | 51 |
Odds ratio (95% CI) | 1.12 (0.55, 2.30), p = 0.7486 | |
History of CV disease | ||
Evaluable n | 19 | 25 |
Odds ratio (95% CI) | 2.30 (0.68, 7.83), p = 0.1822 | |
History of diabetes | ||
Evaluable n | 60 | 53 |
Odds ratio (95% CI) | 1.31 (0.63, 2.75), p = 0.4704 | |
History of cognitive/mental impairments | ||
Evaluable n | 43 | 40 |
Odds ratio (95% CI) | 1.18 (0.49, 2.88), p = 0.7126 |